Less than a tenth of individuals that would benefit from obesity jabs including Wegovy are able to get them, warns the WHO as it issues its initial guidance on the medications.
Considering over a billion individuals worldwide currently obese, it is advocating for broader and more equitable access to GLP-1 medication.
According to projections, more than two billion will be living with obesity by 2030 unless action is taken.
"Our latest guidelines affirms that obesity is a chronic disease that can be managed with thorough and continuous care," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are key obstacles to broad availability to the jabs that can aid individuals in losing considerable body mass, explains the organization.
Skinny Jab Supply Crisis
Even under the present most optimistic outlook, the supply of these medications might only reach approximately 100 million people – less than 10% of eligible patients, according to the health organization.
The guideline calls on nations and manufacturers to expand access, through strategies such as voluntary licensing.
The intellectual property rights on the active ingredient – the core ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Weight-Loss Drugs Work
GLP-1 drugs imitate a body's own hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so individuals reduce food intake.
Patients commonly see weight reduction in the initial weeks of beginning the weekly injections.
Studies suggests patients may regain a significant portion within a year of halting the medication, when their typical hunger resume.
Being above a healthy weight raises your chance for contracting health problems, including diabetes, heart disease, brain attack, and some malignancies.
Obesity affects individuals in all nations and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
